India’s pharma industry has witnessed a significant turnaround in recent years, transitioning from struggling public sector undertakings (PSUs) to becoming a net exporter of bulk drugs and a hub for indigenous medical innovation.
Thanks to the government’s Make in India initiative and targeted industrial reforms, the sector has shifted from a ₹1,930 crore deficit in FY22 to a ₹2,280 crore surplus in FY25, according to recent government data.
This transformation highlights India’s growing capabilities in medical manufacturing, R&D, and innovation — particularly in areas like medical devices and next-generation antibiotics.
A decade-long reversal: From revival warnings to export strength
Back in 2013, a parliamentary panel flagged the need to revive pharmaceutical PSUs, citing inefficiencies, low output, and overdependence on imports for bulk drugs and Active Pharmaceutical Ingredients (APIs).
Fast forward to 2025, and the situation has been dramatically reversed. India is now a net exporter of essential bulk drugs, a feat made possible by investments in production-linked incentive (PLI) schemes, research facilities, and API parks.
The shift reflects not only operational revival but also strategic autonomy in the health sector — a key lesson reinforced by COVID-19 supply disruptions.
Indigenous innovation takes centre stage
One of the landmark achievements during this transformation has been the development of Nafithromycin — India’s first indigenous macrolide antibiotic, marking a major breakthrough in pharma R&D.
Nafithromycin is seen as a milestone in reducing India’s reliance on imported high-value molecules and showcases the ability of Indian labs to innovate globally competitive therapies.
This aligns with India’s broader ambitions to build an innovation-driven bioeconomy, with SMEs, biotech startups, and pharma research units playing a central role.
Medical device production gets ₹3,420 crore boost
Beyond pharmaceuticals, the government has also injected ₹3,420 crore to support the indigenous production of critical medical devices, such as MRI machines and heart implants — equipment India previously depended on imports for.
This initiative is expected to directly benefit MSME manufacturers in the medical technology sector, opening opportunities for local suppliers, component makers, and precision engineering firms.
By building local capacity in med-tech, India not only saves on import bills but also strengthens national healthcare resilience.
Also read: Nima Goos Goos Secures Backing to Scale Globally
MSME impact and forward outlook
The pharma and medical devices revival is opening up major downstream opportunities for MSMEs across India — from formulation units and packaging to logistics and raw material suppliers.
With the shift towards domestic production, compliance-driven exports, and public-private innovation partnerships, MSMEs now have a chance to integrate into high-value global supply chains.
Policy measures, including simplified licensing, quality certifications, and financial incentives under schemes like Startup India and PM Gati Shakti, are helping these enterprises scale and compete internationally.
India’s pharmaceutical revival is no longer a blueprint — it’s an unfolding success story, powered by innovation, indigenous capability, and MSME participation.